Brokers  /  EquityLeaps

EquityLeaps

Moderate risk
🇺🇸 United States · 2-5 years · since 2022-01-10 · EquityLeaps
This is a , not a leveraged forex/CFD broker — listed for reference. If you’re looking for a forex broker, see our forex broker directory.
Unregulated
Visit site ↗
Independent ratingshow third parties score this broker
WikiFX1.49/10
Trustpilot/5
Forex Peace Army/5
🛡️ Been scammed or can’t withdraw from EquityLeaps? Our free assistant writes up your case and shows exactly what to do next →
🇺🇸
No sign that EquityLeaps actively operates in your country (United States). If you were solicited from here, be extra cautious — it may be an unregulated approach or a clone.
49
Moderate risk
Scam Risk Scoremonitored · 2026-07-28
Lower riskHigher risk
  • No verified regulatory license on file
  • No verifiable website or social-media presence
How this score is calculated — view the open algorithm

A transparent weighted score from objective public data — each factor scored 0–100 (higher = riskier), combined by the weights below.

FactorScoreWeight
Regulation & licensing8535%
Company age4515%
Clone / impersonation012%
Withdrawal & exposure complaints012%
Offshore registration108%
Transparency (site/info/social)7810%

Based on public regulatory records, industry databases and independent reviews (Trustpilot, Forex Peace Army). Exit Risk reflects recent negative momentum in real reviews. A risk estimate from public data, not a definitive legal judgment; brokers may request a correction.

Company
Legal nameEquityLeaps
Headquarters🇺🇸 United States
Founded2022-01-10
Years operating2-5 years
Employees0
Official websiteequityleaps.com
Trading conditions
Avg execution speed0 ms
Avg slippage0
Swap rating
Trading cost rating
Monitored traders0
Monitored orders0
Funding & instruments
Deposit methods
Withdrawal methods
Instruments
Registered address
755 Scotland Rd, Orange, New Jersey (NJ), 07050

Regulation & licenses · 0

No valid regulatory license found — high caution advised.

Review analysis AI

EquityLeaps is an unregulated US-registered entity with no public web presence or independent reviews. The absence of regulatory oversight and verifiable information presents a high risk for clients, as there are no guarantees of fund safety or professional conduct. Traders should avoid this broker until credible evidence of its operations and regulation emerges.

Not for
  • Traders seeking regulated brokers
  • Investors requiring transparent operations
  • Anyone without prior independent verification
Period:

Real user reviews

Similar brokers

About EquityLeaps

Overview

EquityLeaps is a financial entity registered in the United States, with a registered address at 755 Scotland Rd, Orange, New Jersey. The company was founded on 10 January 2022, according to public records. However, there is currently no publicly available official website or independent information detailing its operations, services, or target clientele.

This lack of verifiable public presence makes it difficult to assess the firm's business model or the specific financial products it may offer. Traders and investors should approach such entities with caution, especially when no independent sources confirm their activities.

Company Background

EquityLeaps is recorded as a business entity in the state of New Jersey, United States. The company's registration date of January 2022 indicates it is relatively new, with a limited operational history. Its physical address in Orange, New Jersey, provides a point of reference, but without further documentation or a functional website, its corporate structure and management remain opaque.

The absence of any public announcements, press releases, or professional profiles associated with the company suggests that it may not be actively marketed or may operate in a very niche capacity. This lack of transparency is a significant factor for any potential client to consider.

Regulation and Safety

EquityLeaps holds no known regulatory licenses from any financial authority. Our records confirm that the company is not registered with any major financial regulator, including but not limited to the US Commodity Futures Trading Commission (CFTC), the National Futures Association (NFA), or the Securities and Exchange Commission (SEC). This means that clients would not benefit from the protections typically afforded by regulated financial institutions, such as investor compensation schemes or dispute resolution mechanisms.

Operating without regulatory oversight implies that there is no independent body monitoring the company's compliance with financial standards or ethical practices. Clients dealing with unregulated entities assume higher risks, including potential loss of funds without recourse. For those seeking a secure trading environment, a regulated broker is generally recommended.

Products and Services

Due to the unavailability of an official website or any promotional materials, the specific products and services offered by EquityLeaps cannot be determined. It is unclear whether the company provides forex trading, CFD trading, stock brokerage, cryptocurrency exchange, or any other financial services. The name 'EquityLeaps' might suggest a focus on equity markets, but this is purely speculative.

Without verifiable data, it is impossible to confirm the type of trading platforms, instruments, leverage options, or account features the company might offer. Potential clients should be wary of making any commitments without first obtaining detailed, documented information directly from the company.

Conclusion

EquityLeaps remains a largely unknown entity in the financial services space. While it is registered in the United States, the lack of regulatory oversight, combined with the absence of a public-facing website or independent reviews, creates a high degree of uncertainty. Traders are advised to conduct thorough due diligence and consider only regulated and well-established brokers for their financial activities.

In summary, the available information on EquityLeaps is insufficient to form a reliable assessment of its legitimacy or capability. Until further evidence emerges, caution is strongly recommended.

Overview compiled by FXCanary from regulatory records and public data. full EquityLeaps review